» Articles » PMID: 39776795

Prevention of Radiotherapy-induced Pro-tumorigenic Microenvironment by SFK Inhibitors

Overview
Journal Theranostics
Date 2025 Jan 8
PMID 39776795
Authors
Affiliations
Soon will be listed here.
Abstract

Radiotherapy is a widely employed technique for eradication of tumor using high-energy beams, and has been applied to approximately 50% of all solid tumor patients. However, its non-specific, cell-killing property leads to inevitable damage to surrounding normal tissues. Recent findings suggest that radiotherapy-induced tissue damage contributes to the formation of a pro-tumorigenic microenvironment. Here, we utilized two mouse strains and two organ-targeted radiotherapy models to uncover the mechanisms underlying the development of the radiotherapy-induced microenvironment. Radiotherapy-induced tissue damage stimulates infiltration of monocyte-derived macrophages and their differentiation into M2 macrophages, ultimately leading to fibrosis and the formation of a pro-tumorigenic microenvironment. Notably, SRC family kinases (SFKs) emerged as crucial factors in the formation of the radiotherapy-induced pro-tumorigenic microenvironment. SFKs activation in epithelial cells and fibroblasts was triggered by direct exposure to irradiation or M2 macrophage cytokines. Remarkably, the administration of SFK-targeted inhibitors reversed myofibroblast activation, effectively ameliorating fibrosis and the pro-tumorigenic microenvironment in radiated tissues. Further, combined administration of radiotherapy and SFK-targeted inhibitors significantly enhanced the survival of tumor-bearing mice. Reshaping the tissue microenvironment by targeting SFKs is a potential strategy for preventing metastasis and recurrence following radiotherapy. The finding that clinically imperceptible damage can trigger a pro-tumorigenic microenvironment suggests the need for combining SFK-targeted inhibitors with radiotherapy.

References
1.
Peng D, Fu M, Wang M, Wei Y, Wei X . Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022; 21(1):104. PMC: 9033932. DOI: 10.1186/s12943-022-01569-x. View

2.
Braga T, Henao Agudelo J, Camara N . Macrophages During the Fibrotic Process: M2 as Friend and Foe. Front Immunol. 2015; 6:602. PMC: 4658431. DOI: 10.3389/fimmu.2015.00602. View

3.
Glass D, Grossfeld D, Renna H, Agarwala P, Spiegler P, DeLeon J . Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J. 2022; 16(2):84-96. PMC: 9060042. DOI: 10.1111/crj.13466. View

4.
Weber M, Homm A, Muller S, Frey S, Amann K, Ries J . Zoledronate Causes a Systemic Shift of Macrophage Polarization towards M1 In Vivo. Int J Mol Sci. 2021; 22(3). PMC: 7865688. DOI: 10.3390/ijms22031323. View

5.
Redin E, Garmendia I, Lozano T, Serrano D, Senent Y, Redrado M . SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. J Immunother Cancer. 2021; 9(3). PMC: 7931761. DOI: 10.1136/jitc-2020-001496. View